Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells

The exact influence of statins on gefitinib resistance in human non-small cell lung cancer (NSCLC) cells with KRAS mutation alone or KRAS/PIK3CA and KRAS/PTEN comutations remains unclear. This work found that transfection of mutant KRAS plasmids significantly suppressed the gefitinib cytotoxicity in Calu3 cells (wild-type KRAS). Gefitinib disrupted the Kras/PI3K and Kras/Raf complexes in Calu3 cells, whereas not in Calu3 KRAS mutant cells. These trends were corresponding to the expression of pAKT and pERK in gefitinib treatment. Atorvastatin (1 μM) plus gefitinib treatment inhibited proliferation, promoted cell apoptosis, and reduced the AKT activity in KRAS mutant NSCLC cells compared with gefitinib alone. Atorvastatin (5 μM) further enhanced the gefitinib cytotoxicity through concomitant inhibition of AKT and ERK activity. Atorvastatin could interrupt Kras/PI3K and Kras/Raf complexes, leading to suppression of AKT and ERK activity. Similar results were also obtained in comutant KRAS/PTEN or KRAS/PIK3CA NSCLC cells. Furthermore, mevalonate administration reversed the effects of atorvastatin on the Kras/Raf and Kras/PI3K complexes, as well as AKT and ERK activity in both A549 and Calu1 cells. The in vivo results were similar to those obtained in vitro. Therefore, mutant KRAS-mediated gefitinib insensitivity is mainly derived from failure to disrupt the Kras/Raf and Kras/PI3K complexes in KRAS mutant NSCLC cells. Atorvastatin overcomes gefitinib resistance in KRAS mutant NSCLC cells irrespective of PIK3CA and PTEN statuses through inhibition of HMG-CoA reductase-dependent disruption of the Kras/Raf and Kras/PI3K complexes.

[1]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[2]  Ming-Sound Tsao,et al.  K-ras mutations in non-small-cell lung carcinoma: a review. , 2006, Clinical lung cancer.

[3]  M. Ladanyi,et al.  Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling , 2011, Molecular Cancer Therapeutics.

[4]  D. Trinh,et al.  Genetic screen identifies insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer. , 2010, Cancer research.

[5]  Takao Satou,et al.  Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma , 2011, Journal of experimental & clinical cancer research : CR.

[6]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[7]  Patricia Greninger,et al.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. , 2009, Cancer cell.

[8]  Young-Kwang Yoon,et al.  KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach , 2010, Molecular carcinogenesis.

[9]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[10]  D. Polsky,et al.  Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. , 2003, Cancer research.

[11]  C. Der,et al.  Ras Family Signaling: Therapeutic Targeting , 2002, Cancer biology & therapy.

[12]  G. Giaccone,et al.  Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  G. Mills,et al.  Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. , 2010, Cancer cell.

[14]  Jingwu Xie,et al.  Oncogenic KRAS Activates Hedgehog Signaling Pathway in Pancreatic Cancer Cells* , 2007, Journal of Biological Chemistry.

[15]  C. Herrmann.  Ras-effector interactions: after one decade. , 2003, Current opinion in structural biology.

[16]  J. Minna,et al.  Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy , 2011, Molecular Cancer Therapeutics.

[17]  Michalis V. Karamouzis,et al.  Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets , 2007, Nature Reviews Drug Discovery.

[18]  Ji-Youn Han,et al.  Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations , 2010, Investigational New Drugs.

[19]  A. Conney,et al.  Atorvastatin and Celecoxib Inhibit Prostate PC-3 Tumors in Immunodeficient Mice , 2007, Clinical Cancer Research.

[20]  T. Zhao,et al.  Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status , 2008, Journal of Neuro-Oncology.

[21]  M. Sliwkowski,et al.  Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. , 2009, Cancer cell.

[22]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[23]  Michael J. Fry,et al.  Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.

[24]  Y. Jeng,et al.  Downregulation of alpha-fetoprotein expression by LHX4: a critical role in hepatocarcinogenesis. , 2011, Carcinogenesis.

[25]  U. Stenius,et al.  Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells. , 2009, Biochemical pharmacology.

[26]  H. Uramoto,et al.  Cancer esearch apeutics , Targets , and Chemical Biology s of PTEN Expression by Blocking Nuclear Translocation GR 1 in Gefitinib-Resistant Lung Cancer Cells Harboring R ermal Growth Factor Receptor – Activating Mutations , 2010 .

[27]  J. Minna,et al.  Oncogenic KRAS‐induced interleukin‐8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non‐small cell lung cancer , 2012, International journal of cancer.

[28]  M. Kuwano,et al.  Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. , 2004, Molecular cancer therapeutics.

[29]  L. Zang,et al.  Berberine Inhibits Human Hepatoma Cell Invasion without Cytotoxicity in Healthy Hepatocytes , 2011, PloS one.

[30]  P. Jänne,et al.  Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. , 2006, The Journal of clinical investigation.

[31]  Min Yu,et al.  TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers , 2012, Cell.

[32]  Yan Pan,et al.  Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1. , 2012, The international journal of biochemistry & cell biology.

[33]  L. Cantley,et al.  PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.

[34]  Joon-Oh Park,et al.  Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. , 2011, Journal of the National Cancer Institute.

[35]  G. Giaccone,et al.  Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. , 2006, International journal of cancer.